Cancer Gene Therapy

Interleukin-12 Trial Begins

Published in Gene Therapy Weekly, September 4th, 1995

The first gene therapy trial using the biological response modifier interleukin-12 (IL-12) has begun at the University of Pittsburgh Cancer Institute (UPCI), University of Pittsburgh Medical Center (UPMC), physicians announced.

The first patient treated is a 53-year-old woman with advanced breast cancer. Other patients who will be treated with genetically delivered IL-12 include those who have skin tumors resulting from advanced melanoma, or head and neck cancer.

"We are excited to start this trial because pre-clinical studies suggest that IL-12 can effectively destroy tumors, even when it is given in small amounts," said Michael Lotze, M.D.,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry